α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Saraswati, Sarita ^a   Kumar, Shakti ^b   Alhaider, Abdulqader A ^c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b NORTH EASTERN HILL UNIVERSITY   (India)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

santalol; AKT mTOR P70S6K; Angiogenesis; Molecular docking; VEGFR2

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITOR; CASPASE 3; CD31 ANTIGEN; CYSTEINE; FOCAL ADHESION KINASE; GLUTAMIC ACID; HEMOGLOBIN; HISTIDINE; ISOLEUCINE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; P70S6 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; SANTALOL; SERINE; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER INHIBITION; CANCER PREVENTION; CANCER THERAPY; CAPILLARY DENSITY; CAPILLARY TUBE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG ISOLATION; DRUG MEGADOSE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; EX VIVO STUDY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROGEN BOND; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOLECULAR DOCKING; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SANTALUM; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR RING; WESTERN BLOTTING;

MUS MUSCULUS; RATTUS;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; SESQUITERPENES; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887959115     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-147     Document Type: Article

References (45)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31. 10.1038/nm0195-27, 7584949.
2. Ferrara N. VEGF and the quest for tumor angiogenesis factors. Nat Rev Cancer 2002, 2:795-803. 10.1038/nrc909, 12360282.
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257. 10.1038/35025220, 11001068.
4. Stetler Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999, 103:1237-1241. 10.1172/JCI6870, 408361, 10225966.
5. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997, 74:111-122.
6. Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, Onisto M, Santi L, Stetler-Stevenson WG, Albini A. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998, 75:246-253. 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B, 9462715.
7. Abdollahi A, Folkman J. Evading tumour evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010, 13:16-28. 10.1016/j.drup.2009.12.001, 20061178.
8. Zhang X, Dwivedi C. Skin cancer chemoprevention by α-santalol. Front Biosci (Schol Ed) 2011, 3:777-787. 10.2741/s186, 21196411.
9. Dwivedi C, Guan X, Harmsen WL, Voss AL, Goetz-Parten DE, Koopman EM, Johnson KM, Valluri HB, Matthees DP. Chemopreventive effects of alpha santalol on skin tumor development in CD-1 and SENCAR mice. Cancer Epidemiol Biomarkers Prev 2003, 12:151-156.
10. Dwivedi C, Valluri HB, Guan X, Agarwal R. Chemopreventive effects of alpha-santalol on ultraviolet B radiation-induced skin tumor development in SKH-1 hairless mice. Carcinogenesis 2006, 27:1917-1922. 10.1093/carcin/bgl058, 16679309.
11. Bommareddy A, Hora J, Cornish B, Dwivedi C. Chemoprevention by alphasantalol on UVB radiation-induced skin tumor development in mice. Anticancer Res 2007, 27:2185-2188.
12. Arasada BL, Bommareddy A, Zhang X, Bremmon K, Dwivedi C. Effects of alpha-santalol on proapoptotic caspases and p53 expression in UVB irradiated mouse skin. Anticancer Res 2008, 28:129-132.
13. Bommareddy A, Rule B, VanWert AL, Santha S, Dwivedi C. α-santalol, a derivative of sandalwood oil, induces apoptosis in human prostate cancer cells by causing caspase-3 activation. Phytomedicine 2012, 19:804-811. 10.1016/j.phymed.2012.04.003, 22571975.
14. Matsuo Y, Mimaki Y. α-santalol derivatives from santalum album and their cytotoxic activities. Phytochemistry 2012, 77:304-311.
15. Zhang X, Chen W, Guillermo R, Chandrasekher G, Kaushik RS, Young A, Fahmy H, Dwivedi C. Alpha-santalol, a chemopreventive agent against skin cancer, causes G2/M cell cycle arrest in both p53-mutated human epidermoid carcinoma A431 cells and p53 wild-type human melanoma UACC-62 cells. BMC Res Notes 2010, 3:220. 10.1186/1756-0500-3-220, 3161371, 20682067.
16. Corey EJ, Kirst HA, Katzenellenbogen JA. A stereospecific total synthesis of a-santalol. J Am Chem Soc 1970, 1970(92):6314-6319.
17. Saraswati S, Agrawal SS. Brucine, an indole alkaloid from strychnos nuxvomica attenuates VEGF-induced angiogenesis via inhibiting VEGFR2 signaling pathway in vitro and in vivo. Cancer Lett 2013, 332:83-93. 10.1016/j.canlet.2013.01.012, 23348691.
18. Saraswati S, Kanuajia PK, Kumar S, Kumar R, Alhaider AA. Tylophorine, a phenanthraindolizidine alkaloid isolated from tylophora indica exerts antiangiogenic and antitumor activity by targeting vascular endothelial growth factor receptor 2-mediated angiogenesis. Mol Cancer 2013, 12:82. 10.1186/1476-4598-12-82, 3733984, 23895055.
19. Guo S, Colbert LS, Fuller M, Zhang Y, Gonzalez-Perez RR. Vascular endothelial growth factor receptor-2 in breast cancer. Biochem Biophys Acta 1806, 2010:108-121.
20. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk- 1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999, 59:99-106.
21. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309. 10.1126/science.2479986, 2479986.
22. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248. 10.1038/35025215, 11001067.
23. Klagsbrun M, D'Amore P. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996, 7:259-270. 10.1016/S1359-6101(96)00027-5, 8971481.
24. Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, Wähälä K, Montesano R, Schweigerer L. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 1997, 57:2916-2921.
25. Paper DH. Natural products as angiogenesis inhibitors. Planta Med 1998, 64:686-695. 10.1055/s-2006-957559, 9933986.
26. Cao Y, Cao R, Brakenheilm E. Anti-angiogenic mechanisms of diet-derived polyphenols. J Nutr Biochem 2002, 13:380-390. 10.1016/S0955-2863(02)00204-8, 12121824.
27. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention: angiogenesis is a common key target for cancer chemopreventive agents. FASEB J 2002, 16:2-14. 10.1096/fj.01-0300rev, 11772931.
28. Dorai T, Aggarwal BB. Role of chemopreventive agents in cancer therapy. Cancer Lett 2004, 215:129-140. 10.1016/j.canlet.2004.07.013, 15488631.
29. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev 2007, 7:803-815.
30. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999, 237:97-132.
31. Zachary I. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001, 49:568-581. 10.1016/S0008-6363(00)00268-6, 11166270.
32. Matsuo M, Yamada S, Koizumi K, Sakurai H, Saiki I. Tumor-derived fibroblast growth factor-2 exerts lymphangiogenic effects through Akt/mTOR/p70S6kinase pathway in rat lymphatic endothelial cells. Eur J Cancer 2007, 43:1748-1754. 10.1016/j.ejca.2007.04.024, 17570654.
33. Li W, Tan D, Zhang Z, Liang JJ, Brown RE. Activation of Akt-mTORp70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep 2008, 20:713-719.
34. Eliceiri BP, Puente XS, Hood JD, Stupack DG, Schlaepfer DD, Huang XZ, Sheppard D, Cheresh DA. ASrc-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol 2002, 157:149-160. 10.1083/jcb.200109079, 2173263, 11927607.
35. Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, Aggarwal BB, Liu M. Acetyl- 11-keto-β-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 2009, 69:5893. 10.1158/0008-5472.CAN-09-0755, 2724674, 19567671.
36. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Computational Chem 2010, 31:455-461.
37. Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity-A rapid access to atomic charges. Tetrahedron 1980, 36:3219-3228.
38. Wallace AC, Laskowski RA, Thorton JM. LIGPLOT: a program to generate schematic diagram of protein ligand interactions. Protein Eng 1995, 8:127-134. 10.1093/protein/8.2.127, 7630882.
39. Zhang S, Cao Z, Tian H, Shen G, Ma Y, Xie H, Liu Y, Zhao C, Deng S, Yang Y, Zheng R, Li W, Zhang N, Liu S, Wang W, Dai L, Shi S, Cheng L, Pan Y, Feng S, Zhao X, Deng H, Yang S, Wei Y. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clin Cancer Res 2011, 17:4439-4450. 10.1158/1078-0432.CCR-10-3109, 21622720.
40. Agarwal C, Singh RP, Agarwal R. Grape seed extract induces apoptotic death of human prostate carcinoma DU145 cells via caspases activation accompanied by dissipation of mitochondrial membrane potential and cytochrome c release. Carcinogenesis 2002, 23:1869-1876. 10.1093/carcin/23.11.1869, 12419835.
41. Saraswati S, Pandey M, Mathur R, Agrawal SS. Boswellic acid inhibits inflammatory angiogenesis in a murine sponge model. Microvasc Res 2011, 82:263-268. 10.1016/j.mvr.2011.08.002, 21864545.
42. Agrawal SS, Saraswati S, Mathur R, Pandey M. Brucine, a plant derived alkaloid inhibits inflammatory angiogenesis in a murine sponge model. Biomedicine and Preventive Nutrition 2011, 1(3):180-185.
43. Saraswati S, Agrawal SS. Strychnine inhibits inflammatory angiogenesis in mice via down regulation of VEGF, TNF-α and TGF-β. Microvasc Res 2013, 87:7-13.
44. Agrawal SS, Saraswati S, Mathur R, Pandey M. Antitumor properties of boswellic acid against Ehrlich ascites cells bearing mouse. Food Chem Toxicol 2011, 49:1924-1934. 10.1016/j.fct.2011.04.007, 21513768.
45. Agrawal SS, Saraswati S, Mathur R, Pandey M. Cytotoxic and antitumor effects of brucine on Ehrlich ascites tumor and human cancer cell line. Life Sci 2011, 89(5-6):147-158.